User:Mr. Ibrahem/Safinamide

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Safinamide
Clinical data
Trade namesXadago, Onstryv, others
Other namesEMD-1195686, PNU-15774E;
(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl] methylamino]propanamide
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • Fetal malformations in animal studies[1]
Routes of
administration		By mouth
Drug classMonoamine oxidase inhibitor[2]
Legal status
Legal status
Pharmacokinetic data
Bioavailability95%
Protein binding88–90%
MetabolismAmidases, glucuronidation
Elimination half-life20–30 hrs
Excretion76% Kidney, 1.5% faeces
Identifiers
  • N2-{4-[(3-fluorobenzyl)oxy]benzyl}-L-alaninamide
Chemical and physical data
FormulaC17H19FN2O2
Molar mass302.349 g·mol−1
3D model (JSmol)
  • O=C(N)[C@@H](NCc2ccc(OCc1cccc(F)c1)cc2)C
  • InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1 checkY
  • Key:NEMGRZFTLSKBAP-LBPRGKRZSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Safinamide, sold under the brand name Xadago among others, is a medication used as an add-on treatment for Parkinson's disease with off episodes.[3] Specifically it is used together with levodopa-carbidopa.[3] It is taken by mouth.[3]

Common side effects include trouble sleeping, difficulty controlling movements, sleepiness, dizziness, headache, cataracts, and low blood pressure with standing.[2] Other side effects may include high blood pressure, serotonin syndrome, sudden onset of sleep, an urge to gamble, and hallucinations.[3] is an inhibitor of monoamine oxidase B and therefore increases levels of dopamine.[2]

Safinamide was approved for medical use in Europe in 2015,[2] the United States in 2017,[3] and Canada in 2019.[5] In the United Kingdom a month of medication costs the NHS about £70 as of 2021.[4] In the United States this amount costs about 1,000 USD.[6]

References[edit]

  1. ^ "Summary of the risk management plan (RMP) for Xadago (safinamide)" (PDF). European Medicines Agency. January 2015. Archived (PDF) from the original on 2017-03-29. Retrieved 2021-08-04.
  2. ^ a b c d e "Xadago". Archived from the original on 6 March 2021. Retrieved 10 October 2021.
  3. ^ a b c d e f g "Safinamide Monograph for Professionals". Drugs.com. Archived from the original on 5 October 2021. Retrieved 10 October 2021.
  4. ^ a b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 447. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  5. ^ Government of Canada, Health Canada (2012-04-25). "Drug Product Database Online Query". health-products.canada.ca. Archived from the original on 2021-08-29. Retrieved 2019-07-21.
  6. ^ "Xadago Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 17 January 2021. Retrieved 10 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Safinamide&oldid=1213827166"